Cite
English BC, Baum CE, Adelberg DE, et al. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag. 2010;6:579-83doi: 10.2147/TCRM.S14303.
English, B. C., Baum, C. E., Adelberg, D. E., Sissung, T. M., Kluetz, P. G., Dahut, W. L., Price, D. K., & Figg, W. D. (2010). A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Therapeutics and clinical risk management, 6579-83. https://doi.org/10.2147/TCRM.S14303
English, Bevin C, et al. "A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer." Therapeutics and clinical risk management vol. 6 (2010): 579-83. doi: https://doi.org/10.2147/TCRM.S14303
English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag. 2010 Nov 19;6:579-83. doi: 10.2147/TCRM.S14303. PMID: 21151627; PMCID: PMC2999510.
Copy
Download .nbib